P-212 The cost of survival gain in metastatic colorectal cancer (mCRC) in France

Whalen, John; Chang, Jane; Ozer-Stillman, I.; Ambavane, Apoorva; Ngai, Chris

doi:10.1093/annonc/mdv233.209

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Looking at an individual therapeutic class, two studies by Whalen et al estimated the incremental cost per month of median OS (mOS) gained with the use of approved targeted therapies for colorectal cancer for first, second and third-line treatment of mCRC in Spain [16] and in France [17]. Both studies compared the treatment options bevacizumab, cetuximab, panitumumab, aflibercept and regorafenib and found the survival gain with targeted therapies to be higher in first-line than in second- or third-line treatment.…”

Section: What Is Happening To Launch Prices?mentioning

confidence: 99%

“…1Cost per month of median overall survival gained versus treatment approval date, in France (€). Author’s analysis based on data from Whalen et al [17]. FOLFIRI folinic acid, fluorouracil and irinotecan, FOLFOX4 folinic acid, fluorouracil and oxaliplatin, IFL irinotecan, fluorouracil, and leucovorin, mOS median overall survival …”

Section: What Is Happening To Launch Prices?mentioning

confidence: 99%

See 1 more Smart Citation

Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer

Barron

Wilsdon

2016

Pharm Med

View full text Add to dashboard Cite

Although significant progress has been made in the past decade in the treatment of both common and rare cancers, there has been significant concerns about the cost, and especially the value, of certain new oncology drugs. These concerns touch upon a number of issues regarding the price of these medicines, the value they deliver and the ability of healthcare systems to fund them. This paper looks at these perceptions and the extent to which they apply across different oncology products. Whilst it is acknowledged there is evidence that the launch price of pharmaceutical treatments for some forms of cancer has been rising in recent years, this is not uniformly the case; we find evidence to the contrary for some forms of cancer. This is illustrated by the cases of breast and colorectal cancer. We find cancer medicine prices depend on a number of factors, including pre-existing treatment options within a therapeutic class. Indeed, a number of studies have focused on the cost of treatment per month of overall survival gained as a simple (although partial) metric to judge value for money. Given the importance of oncology products being used in combination, developing similar approaches to capturing the overall cost of treatment will be crucial.

show abstract

Section: What Is Happening To Launch Prices?mentioning

confidence: 99%

Section: What Is Happening To Launch Prices?mentioning

confidence: 99%

Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer

Barron

Wilsdon

2016

Pharm Med

View full text Add to dashboard Cite

show abstract

Regorafenib: A Review in Metastatic Colorectal Cancer

Dhillon

2018

Drugs

View full text Add to dashboard Cite

Regorafenib (Stivarga) is an oral small-molecule multiple kinase inhibitor. It is indicated worldwide for patients with metastatic colorectal cancer (mCRC). In the EU and USA it is indicated for patients with mCRC who have been previously treated with, or are not considered candidates for available therapies, including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy. In Japan, it is indicated for the treatment of unresectable, advanced/recurrent CRC. The addition of regorafenib to best supportive care prolonged median overall survival (OS; by up to 2.5 months) and progression-free survival (PFS; by up to 1.5 months) relative to the addition of placebo in double-blind phase 3 studies (CORRECT and CONCUR) in patients with mCRC who had progressed after failure of standard therapy. Health-related quality of life was not adversely affected with regorafenib relative to placebo. A large open-label phase 3 study (CONSIGN) and several large real-world studies supported the efficacy of regorafenib in this setting. Regorafenib had a generally manageable tolerability profile, which was consistent with the profile of a typical small-molecule multiple kinase inhibitor. Treatment-related adverse events (AEs), mostly of mild or moderate severity, were reported in the majority of patients receiving regorafenib, with dermatological toxicities and liver enzyme elevations among the most common AEs. Although identification of biomarkers/parameters predicting efficacy outcomes with regorafenib will help to individualize therapy, current evidence indicates that regorafenib is a valuable treatment option for patients with refractory mCRC who have a very poor prognosis.

show abstract

P-212 The cost of survival gain in metastatic colorectal cancer (mCRC) in France

Cited by 2 publications

References 0 publications

Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer

Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer

Regorafenib: A Review in Metastatic Colorectal Cancer

Contact Info

Product

Resources

About